Deciphera Pharmaceuticals (DCPH) and Clovis Oncology (CLVS) Head-To-Head Analysis

Deciphera Pharmaceuticals (NASDAQ: DCPH) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Insider & Institutional Ownership

44.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 12.5% of Clovis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Deciphera Pharmaceuticals and Clovis Oncology’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Deciphera Pharmaceuticals N/A N/A -$25.94 million N/A N/A
Clovis Oncology $80,000.00 32,769.31 -$349.13 million ($8.28) -6.46

Deciphera Pharmaceuticals has higher earnings, but lower revenue than Clovis Oncology.


This table compares Deciphera Pharmaceuticals and Clovis Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Deciphera Pharmaceuticals N/A N/A N/A
Clovis Oncology -947.47% -122.06% -38.84%

Analyst Recommendations

This is a summary of current recommendations and price targets for Deciphera Pharmaceuticals and Clovis Oncology, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Deciphera Pharmaceuticals 0 0 5 0 3.00
Clovis Oncology 0 6 11 0 2.65

Deciphera Pharmaceuticals currently has a consensus price target of $43.40, suggesting a potential upside of 69.60%. Clovis Oncology has a consensus price target of $90.31, suggesting a potential upside of 68.83%. Given Deciphera Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Deciphera Pharmaceuticals is more favorable than Clovis Oncology.


Deciphera Pharmaceuticals beats Clovis Oncology on 7 of the 10 factors compared between the two stocks.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply